MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
FDMT stock logo

FDMT

4D Molecular Therapeutics, Inc.

$11.66
0.67
 (6.1%)
Exchange:  
Market Cap:   544.551M
Shares Outstanding:   14.835M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  David H. Kirn
Full Time Employees:  227
Address: 
5858 Horton Street
EmeryVille
CA
94608
US
Website:  https://www.4dmoleculartherapeutics.com
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

🔒 You are currently logged out

Login

It’s free

View full analyst estimates

Earnings Call

🔒 You are currently logged out

Login

It’s free

Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

(* All numbers are in thousands)

🔒 You are currently logged out

Login

It’s free

Balance Sheet

(* All numbers are in thousands)

🔒 You are currently logged out

Login

It’s free

Cash Flow Statement

(* All numbers are in thousands)

🔒 You are currently logged out

Login

It’s free

Analyst Estimates

(* All numbers are in thousands)

🔒 You are currently logged out

Login

It’s free

Current Key Metrics

🔒 You are currently logged out

Login

It’s free

Forward P/E Ratios

🔒 You are currently logged out

Login

It’s free

SWOT Analysis

🔒 You are currently logged out

Login

It’s free

At what price to buy it? –
Intrinsic Value Calculator


Calculate FDMT Intrinsic Value

🔒 You are currently logged out

Login

It’s free

Could not create stock discussion for FDMT

Relevant news

21-11-2025 19:43
4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript
14-11-2025 16:05
4DMT Announces New Employment Inducement Grants
30-09-2025 05:08
4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors
MARKETSnap
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read